BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference
Key Highlights
- ➤BlossomHill to present at Guggenheim’s 3rd Annual Healthcare Innovations Conference
- ➤Management fireside chat scheduled for November 10, 2026, at 3:00 pm Eastern Time
- ➤BH-30643 received Fast Track designation for EGFR C797S resistance after 3rd generation EGFR TKI treatment
- ➤BH-30236 clinical trial targets relapsed or refractory AML and higher-risk MDS
- ➤BH-501284 is a preclinical selective pan-KRAS Switch-II inhibitor
Expert Statements
J. Jean Cui, Founder and leader of BlossomHill Therapeutics
“applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment”
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced its participation in Guggenheim’s 3(rd) Annual Healthcare Innovations Conference being held at the Intercontinental Boston. Management will participate in a fireside chat on Tuesday, November 10, 2026, at 3:00 pm Eastern Time and will also participate in one-on-one investor meetings.
An audio webcast of the fireside chat can be accessed on the Events & Presentations page of the Investors section of BlossomHill’s website. An archived replay will be available for 90 days.
Get started
Create a free account to read the full story.